BioSpace News Archive

Regulatory News: Median Technologies (Paris:AMLDT), The Imaging Phenomics Company® (ALMDT) announced today that it has been awarded the Euronext European Rising Tech Label. The European Rising Tech Label recognizes 98 top-performing companies among more than 350 small and mi

The global pharmaceutical analytical testing services is poised to experience spend growth of more than USD 5 billion between 2019-2023 at a CAGR of over 8%.

Troy-based Jagannathan Neurosurgery is pleased to announce the addition of it’s second board-certified neurosurgeon, Dr. M. Adam Kremer.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-313 in patients with persistent tinnitus of at least moderate severity.

Revolution Medicines, Inc. (Nasdaq:RVMD) today announced that it has commenced an underwritten public offering of 5,500,000 shares of common stock.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced registered direct offering of approximately 4,938,278 of the Company’s ordinary shares, at a purchase price of $1.8225 per ordinary share, priced at-the-market under Nasdaq Rules

McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2021 financial results before market open on Monday, August 3, 2020.

9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today the Company has appointed Michael T. Constantino to its board of directors.

ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab

Trodelvy significantly improved progression-free survival (PFS) and overall survival (OS) in previously-treated brain metastasis negative patients with advanced mTNBC The safety profile of Trodelvy was consistent with the FDA-approved label and no new safety signals were observed Trodelvy is the first antibody-drug conjugate (ADC) shown to improve clinical outcomes in people with relapsed or refractory mTNBC who have received two prior therapies sBLA submission seeking full approval